NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA
Clinical trials for NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a pill keep mantle cell lymphoma away? new study tests ibrutinib maintenance
Disease control CompletedThis study tested whether the drug ibrutinib can safely keep mantle cell lymphoma from returning after initial chemotherapy. Thirty-seven patients who had already responded to chemo took ibrutinib as a maintenance therapy. Researchers tracked how long patients stayed cancer-free …
Matched conditions: NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Matched conditions: NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC